Strategic Focus Clinical-stage oncology company pursuing a novel MEK inhibitor class (Deep Cyclic Inhibitors) with lead candidate atebimetinib for MAPK pathway-driven tumors, including pancreatic cancer, highlighting potential opportunities to align with partners or vendors that support oncology clinical development, trial management, and regulatory strategies.

Leadership & Finance Raised funding of around $200M and appointing a new Chief Financial Officer, signaling readiness for expanded clinical programs and potential needs for strategic treasury management, budgeting for later-stage trials, and external partnerships.

Clinical Momentum Active Phase 2a program in first-line pancreatic cancer with ongoing data Dissemination at major conferences (ASCO, AACR) indicating near-term opportunities for collaboration with contract research organizations, translational science vendors, and diagnostic partners to support trial execution and biomarker work.

Engagement & Communications Dedicated investor relations leadership and frequent conference appearances create openings for outsourced investor communications, corporate storytelling, and market access messaging services tailored to oncology investors and potential collaborators.

Market Positioning Small-to-mid cap biotech with revenue in the tens of millions and robust growth aspirations; potential sales opportunities for CROs, manufacturing partners, and software/cloud providers that support clinical data management, trial analytics, and regulatory submissions to accelerate pipeline progression.